Head and Neck Cancer

November 4, 2019 — Oncology News & Updates

Xospata Extends Overall Survival in Patients with FLT3 Mutation–Positive Relapsed or Refractory Acute Myeloid Leukemia
Published Results from KEYNOTE-048 Trial Show Extended Survival with Keytruda in Advanced Head and Neck Cancers
Discussing Costs of Genomic Testing with Patients

Oral Cancer and Sex in the Era of HPV Infection

San Francisco, CA—The increasing rate of infection with the human papillomavirus (HPV) in the United States has changed the field of head and neck cancer, or oral cancer, and HPV infection now causes a growing majority (70%-90%) of oropharyngeal squamous-cell carcinomas. As its incidence is rising, so is patients’ curiosity about what sets this cancer apart from other malignancies.

Low Survival in Patients with Head and Neck Cancers Linked to Delays in Radiation Therapy After Surgery

Corbin Davis

Current National Comprehensive Cancer Network guidelines recommend initiating radiation therapy within 6 weeks of tumor resection, but the benefits of shorter time to radiation therapy, including locoregional control and survival, remain inconclusive.

Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer

Eric Allan, MD

Eric Allan, MD, discusses the clinical significance of his research and case study, “Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer.”

Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419

Carryn Anderson, MD

Carryn Anderson, MD, discusses the clinical significance of her research on, “Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419.”

Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer

Meg Barbor, MPH

Scottsdale, AZ—Therapeutic, low-level laser therapy (LLLT) reduces pain and accelerates the resolution of oral mucositis (OM) in patients with head and neck cancer receiving chemoradiotherapy (CRT), according to Eric Allan, MD.

Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419

Meg Barbor, MPH

Scottsdale, AZ—The superoxide dismutase mimetic GC4419 markedly reduced the incidence, intensity, and duration of severe oral mucositis in a study of patients with head and neck cancer.

Prophylactic Gabapentin Linked to Weight Loss, Narcotic Dependency

Meg Barbor, MPH

Scottsdale, AZ—Patients with oropharyngeal cancer undergoing radiation therapy experienced diminished narcotic dependency and weight loss with the use of prophylactic gabapentin.

Infrastructure Issues in the US Drug Supply: Where Did the Drugs Go?

Timothy G. Tyler, PharmD, FCSHP

North America is facing a shortage of certain drugs, and you do not have to be a pharmacist buyer tasked with procurement to realize our drug supply is under pressure. Governmental and professional groups—including the US Food and Drug Administration (FDA), American Society of Clinical Oncology (ASCO), Institute for Safe Medication Practices (ISMP), Association of Community Cancer Center, and American Pharmacists Associ ation, among others—have been stating that this is a serious problem that may not be resolved anytime soon.

Concurrent Chemotherapy with Reirradiation for Head and Neck Cancer

Concomitant chemotherapy with reirradiation offers a cure for select patients with recurrent head and neck cancer in a previously irradiated area. With the findings of 2-year survival in 25% of patients, the researchers noted the importance of choosing the correct patients for this therapy. Previous concurrent chemoradiotherapy was associated with poor survival outcomes. In addition, there was significant risk of sever toxicity, with 20% of patients experiencing treatment-related death.

Results 1 - 10 of 10